New research data on the epidemiology of advanced prostate cancer here in the US has confirmed something that has long been understood (albeit not previously as well documented). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: access, advanced, edpidemiology, risk | Leave a comment »
For many years now, here in the USA, access to FDA-approved drugs for the treatment of cancer and other severe forms of disorder have been guaranteed under Medicare. … READ MORE …
Filed under: Management, Treatment | Tagged: access, advocacy, drug, FDA-approved, therapy | 1 Comment »
Here in the US, according to news reports issued late on Friday, a federal court in New Jersey invalidated the last remaining patent held by Johnson & Johnson on their formulation of abiraterone acetate, known as Zytiga, and used in the treatment of castration-resistant forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, acatate, access, patent, Zytiga | 6 Comments »
The issue as to whether the new, so-called “right-to-try” legislation is a good idea or not is contentious and your sitemaster has no interest in getting into that discussion. What is a fact is that it has now been signed into law. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: "right to try", access, bill, drug, investigational, law | 2 Comments »
It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, availability, Provenge, sipuleucel-T | 2 Comments »
Readers who are interested in a current assessment of issues affecting the quality of (and access to) prostate cancer care services for those living in rural communities across America may want to download and review the two articles listed below. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: access, care, quality, rural | Leave a comment »
In an article published on Monday September 28, in Pharmaceutical Executive (a well-known biopharmaceutical industry trade journal) a senior health care public relations executive recently laid out a detailed rationale for why the industry needs to do a better job … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: access, cost, drug, life, price, survival, value | 5 Comments »
As all our regular readers will be well aware, it is not enough, in the UK, for a new cancer drug to be approved for use by the European Union and its European Medicines Agency. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, cost, drug, NICE, price, value | 5 Comments »
The issue of sociodemographic inequality in the delivery of cancer care is well understood in America — and we don’t really know how to provide a high quality of care to those who are disadvantaged by economic factors, racial factors, or other demographic factors (such a rural vs. urban issues of access to care). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: access, América, Australia, care, sociodemography, socioeconomics | Leave a comment »
In a less than entirely surprising move, the UK’s National Institute for Health and Care Excellence has rejected Bayer’s initial application for coverage of radium-223 (Xofigo) under the National Health Service. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: access, NICE, radium-223 | 1 Comment »
According to a media release issued earlier today, Dendreon is planning to make sipuleucel-T (Provenge) available in Europe, beginning with Germany and the United Kingdom. However, the media release is short on any precision regarding the dates of such availability. … READ MORE …
Filed under: Management, Treatment | Tagged: access, Europe, sipuleucel-T | Leave a comment »
Here in the USA — and in some other countries too — there is an ongoing debate about whether patients should have broad access to their personal health records (including things like laboratory results, physician notes, etc.). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: access, health, information, personal, record | 16 Comments »
In yet another utterly unsurprising “research” finding, a new article in the Journal of Urology has shown that — in the USA — minority prostate cancer patients and prostate cancer patients treated under Medicaid are less likely to have their prostates removed at high-experience and high-volume hospitals where there is high use of robot-assisted surgical techniques. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: access, Medicaid, minority, outcome, quality, surgery, volume | 5 Comments »
Following the rapid approval of enzalutamide (Xtandi®; formerly known as MDV3100) by the U.S. Food & Drug Administration (FDA), the developers have moved just as rapidly to be able to make the product available to men with metastatic, castration-resistant prostate cancer who have received prior treatment with docetaxel-based chemotherapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: access, enzalutamide | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 